HIV 감염의 정신의학적 이해와 치료적 고려점

키워드

참고문헌 (99)

1. Fanales-Belasio E, "HIV virology and pathogenetic mechanisms of infection : a brief overview", Ann Ist Super Sanita, 46, pp.5~14 (2010)
2. Antiretroviral Therapy Cohort C, "Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies", Lancet HIV, 4, pp.e349~e356 (2017)
3. "Fast-track: ending the AIDS epidemic by 2030"[URL]
4. Clayson DJ, "A comparative review of healthrelated quality-of-life measures for use in HIV", AIDS clinical trials, 2006, pp.24, 751~765
5. "Global HIV and AIDS statistics-2020 fact sheet"[URL]
6. 2019 Annual report on the notified HIV, "AIDS in Korea", Park O, 2020
7. Sherr L, "HIV infection associated post-traumatic stress disorder and post-traumatic growth--a systematic review", Psychol Health Med, 16, pp.612~629 (2011)
8. Neigh GN, "PTSD co-morbid with HIV: separate but equal, or two parts of a whole?", Neurobiol Dis, 92, pp.116~123 (2016)
9. Gaynes BN, "Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population", Psychosom Med, 70, pp.505~511 (2008)
10. Hartzler B, "Christopher Mathews W, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States", AIDS Behav, 21, pp.1138~1148 (2017)
11. Rabkin JG, "HIV and depression: 2008 review and update", Curr HIV, 2008, pp.5, 163~171
12. Sadock BJ, "Kaplan and Sadock’s comprehensive textbook of psychiatry", pp.2252~ (2017), Wolters Kluwer
13. 최윤수, "Epidemiological characteristics of HIV infected Korean: Korea HIV", AIDS Cohort Study, 2019, pp.41, 1~9[DOI]
14. 송준영, "Depression Among HIV-infected Patients in Korea: Assessment of Clinical Significance and Risk Factors", Infection and Chemotherapy, 45(2), pp.211~216 (2013), 대한감염학회
15. Blank MB, "A multisite study of the prevalence of HIV with rapid testing in mental health settings", Am J Public Health, 104, pp.2377~2384 (2014)
16. Mimiaga MJ, "The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men", J Acquir Immune Defic Syndr, 68, pp.329~336 (2015)
17. Blank MB, "Co-occurrence of HIV and serious mental illness among medicaid recipients", Psychiatr Serv, 53, pp.868~873 (2002)
18. Uthman OA, "Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis", Curr HIV, 2014, pp.11, 291~307
19. Wykowski J, "Associations between anxiety and adherence to antiretroviral medications in low-and middle-income countries : a systematic review and meta-analysis", AIDS Behav, 23, pp.2059~2071 (2019)
20. Kovalevich J, "Neuronal toxicity in HIV CNS disease", Future Virol, 7, pp.687~698 (2012)
21. Hazleton JE, "Novel mechanisms of central nervous system damage in HIV infection", HIV AIDS(Auckl), 2, pp.39~49 (2010)
22. Bachis A, "Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons", J Neurosci, 32, pp.9477~9484 (2012)
23. Zunszain PA, "Glucocorticoids, cytokines and brain abnormalities in depression", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.722~729 (2011)
24. Boasso A, "HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation", PLoS One, 3, pp.e2961~ (2008)
25. Dantzer R, "From inflammation to sickness and depression : when the immune system subjugates the brain", Nat Rev Neurosci, 9, pp.46~56 (2008)
26. Dantzer R, "Inflammation-associated depression : from serotonin to kynurenine", Psychoneuroendocrinology, 36, pp.426~436 (2011)
27. Byakwaga H, "The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy", J Infect Dis, 210, pp.383~391 (2014)
28. Byakwaga H, "The kynurenine pathway of tryptophan catabolism and AIDS-associated Kaposi sarcoma in Africa", J Acquir Immune Defic Syndr, 70, pp.296~303 (2015)
29. Martinez P, "Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans", J Acquir Immune Defic Syndr, 65, pp.456~462 (2014)
30. Saloner R, "Effects of comorbidity burden and age on brain integrity in HIV", AIDS, 33, pp.1175~1185 (2019)
31. O’Connor EE, "Reliability of white matter microstructural changes in HIV infection : meta-analysis and confirmation", AJNR Am J Neuroradiol, 38, pp.1510~1519 (2017)
32. O’Connor EE, "Brain structural changes following HIV infection : meta-analysis", AJNR Am J Neuroradiol, 39, pp.54~62 (2018)
33. Cysique LA, "HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults : a(1)H MRS study", PLoS One, 8, pp.e61738~ (2013)
34. Ernst T, "Lower brain glutamate is associated with cognitive deficits in HIV patients : a new mechanism for HIVassociated neurocognitive disorder", J Magn Reson Imaging, 32, pp.1045~1053 (2010)
35. Chang L, "A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age", Neuroimage, 23, pp.1336~1347 (2004)
36. Chang L, "Greater than age-related changes in brain diffusion of HIV patients after 1 year", J Neuroimmune Pharmacol, 3, pp.265~274 (2008)
37. Lu H, "Inflammation and risk of depression in HIV : prospective findings from the multicenter AIDS cohort study", Am J Epidemiol, 188, pp.1994~2003 (2019)
38. Hileman CO, "Inflammation, immune activation, and antiretroviral therapy in HIV", Curr HIV, 2017, pp.14, 93~100
39. Wada NI, "The effect of HAARTinduced HIV suppression on circulating markers of inflammation and immune activation", AIDS, 29, pp.463~471 (2015)
40. Vrouenraets SM, "Efavirenz : a review", Expert Opin Pharmacother, 8, pp.851~871 (2007)
41. Clifford DB, "Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals", Ann Intern Med, 143, pp.714~721 (2005)
42. Treisman GJ, "Neuropsychiatric effects of HIV antiviral medications", Drug Saf, 39, pp.945~957 (2016)
43. Decloedt EH, "Neuronal toxicity of efavirenz : a systematic review", Expert Opin Drug Saf, 12, pp.841~846 (2013)
44. Peyriere H, "Management of sudden psychiatric disorders related to efavirenz", AIDS, 15, pp.1323~1324 (2001)
45. Robertson KR, "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort", Neurology, 74, pp.1260~1266 (2010)
46. Thangaraj A, "HIV-1 TAT-mediated microglial activation : role of mitochondrial dysfunction and defective mitophagy", Autophagy, 14, pp.1596~1619 (2018)
47. Tripathi A, "Antiretroviral-mediated microglial activation involves dysregulated autophagy and lysosomal dysfunction", Cells, 8 (2019)
48. Akay C, "Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system", J Neurovirol, 20, pp.39~53 (2014)
49. Letendre S, "Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system", Arch Neurol, 65, pp.65~70 (2008)
50. Varatharajan L, "The transport of anti-HIV drugs across blood-CNS interfaces : summary of current knowledge and recommendations for further research", Antiviral Res, 82, pp.A99~109 (2009)
51. Gong Y, "Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment", Expert Opin Drug Metab Toxicol, 15, pp.417~427 (2019)
52. National survey on HIV, "AIDS knowledge, attitudes, beliefs, and behaviors in the general population, 2015", Lee BK, 2015
53. 2008HIV, "AIDS knowledge, attitudes, belief, and behaviors survey", Kim SB, 2008
54. Earnshaw VA, "From conceptualizing to measuring HIV stigma : a review of HIV stigma mechanism measures", AIDS Behav, 13, pp.1160~1177 (2009)
55. Earnshaw VA, "HIV stigma mechanisms and wellbeing among PLWH : a test of the HIV stigma framework", AIDS Behav, 17, pp.1785~1795 (2013)
56. Greene MC, "Mental health and social support among HIV-positive injection drug users and their caregivers in China", AIDS Behav, 17, pp.1775~1784 (2013)
57. Hosek S, "Preventing HIV among adolescents with oral PrEP : observations and challenges in the United States and South Africa", J Int AIDS Soc, 19, pp.21107~ (2016)
58. Lowther K, "Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy(ART) : a systematic review", Int J Nurs Stud, 51, pp.1171~1189 (2014)
59. Glynn TR, "Pathways to health: an examination of HIV-related stigma, life stressors, depression, and substance use", Int J Behav Med, 26, pp.286~296 (2019)
60. Schuster R, "The influence of depression on the progression of HIV : direct and indirect effects", Behav Modif, 36, pp.123~145 (2012)
61. Durvasula R, "Substance abuse treatment in persons with HIV", AIDS : challenges in managing triple diagnosis, 2014, pp.40, 43~52
62. Gonzalez JS, "Depression and HIV", AIDS treatment nonadherence : a review and meta-analysis, 2011, pp.58, 181~187
63. Mitchell AJ, "Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis", Br J Psychiatry, 201, pp.435~443 (2012)
64. Watkins CC, "Cognitive impairment in patients with AIDS-prevalence and severity", HIV AIDS(Auckl), 7, pp.35~47 (2015)
65. Rukundo GZ, "Burden of suicidal ideation and attempt among persons living with HIV and AIDS in semiurban Uganda", AIDS Res Treat, 2016, pp.3015468~ (2016)
66. Pence BW, "Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States", JAMA Psychiatry, 75, pp.379~385 (2018)
67. Hammond ER, "Cocaine use may be associated with increased depression in persons infected with HIV", AIDS Behav, 20, pp.345~352 (2016)
68. Monroe AK, "Heavy alcohol use is associated with worse retention in HIV care", J Acquir Immune Defic Syndr, 73, pp.419~425 (2016)
69. Malbergier A, "Alcohol dependence and CD4 cell count : is there a relationship", AIDS Care, 27, pp.54~58 (2015)
70. Soontornniyomkij V, "Effects of HIV and methamphetamine on brain and behavior : Evidence from human studies and animal models", J Neuroimmune Pharmacol, 11, pp.495~510 (2016)
71. Rabkin JG, "Mood and substance use disorders in older adults with HIV", AIDS : methodological issues and preliminary evidence, 2004, pp.18(Suppl 1), S43~S48
72. Meyer JP, "Substance abuse, violence, and HIV in women: a literature review of the syndemic", J Womens Health (Larchmt), 20, pp.991~1006 (2011)
73. Chander G, "Substance abuse and psychiatric disorders in HIV-positive patients : epidemiology and impact on antiretroviral therapy", Drugs, 66, pp.769~789 (2006)
74. Hill LM, "Anxiety and depression strongly associated with sexual risk behaviors among networks of young men in Dar es Salaam, Tanzania", AIDS Care, 29, pp.252~258 (2017)
75. Armstrong G, "Association of depression, anxiety, and suicidal ideation with high-risk behaviors among men who inject drugs in Delhi, India", J Acquir Immune Defic Syndr, 64, pp.502~510 (2013)
76. Kang CR, "Suicidal ideation and suicide attempts among human immunodeficiency virus-infected adults : differences in risk factors and their implications", AIDS Care, 28, pp.306~313 (2016)
77. Chochinov HM, "Desire for death in the terminally ill", Am J Psychiatry, 152, pp.1185~1191 (1995)
78. Vance DE, "A model of cognitive decline and suicidal ideation in adults aging with HIV", J Neurosci Nurs, 42, pp.150~156 (2010)
79. Nakimuli-Mpungu E, "Process evaluation of a randomized controlled trial of group support psychotherapy for depression treatment among people with HIV", AIDS in northern Uganda, 2017, pp.53, 991~1004
80. Korthuis PT, "Substance abuse treatment in human immunodeficiency virus : the role of patient-provider discussions", J Subst Abuse Treat, 35, pp.294~303 (2008)
81. Lofgren SM, "Systematic review of interventions for depression for people living with HIV in Africa", AIDS Behav, 22, pp.1~8 (2018)
82. DeSilva KE, "Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine", AIDS, 15, pp.1281~1285 (2001)
83. Pollack TM, "Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients", Pharmacotherapy, 29, pp.1386~1391 (2009)
84. Adams C, "Mental health problems in people living with HIV:changes in the last two decades: the London experience 1990-2014", AIDS Care, 28(Suppl 1), pp.56~59 (2016)
85. Asch SM, "Underdiagnosis of depression in HIV : who are we missing", J Gen Intern Med, 18, pp.450~460 (2003)
86. Pence BW, "Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care", AIDS, 26, pp.656~658 (2012)
87. Mugavero MJ, "Elements of the HIV care continuum : Improving engagement and retention in care", Top Antivir Med, 24, pp.115~119 (2016)
88. Norberg A, "Experiences of HIV-infected adults and healthcare providers with healthcare delivery practices that influence engagement in US primary healthcare settings : a qualitative systematic review", JBI Database System Rev Implement Rep, 17, pp.1154~1228 (2019)
89. Greene J, "Provider behaviors contributing to patient self-management of chronic illness among underserved populations", J Health Care Poor Underserved, 16, pp.808~824 (2005)
90. Bofill LM, "Patient-provider perceptions on engagement in HIV care in Argentina", AIDS Care, 26, pp.602~607 (2014)
91. Sears B, "HIV discrimination in health care services in Los Angeles county: The results of three testing studies", Washington and Lee Journal of Civil Rights and Social Justice, 15 (2008)
92. Rogers SJ, "Layered stigma among health-care and social service providers toward key affected populations in Jamaica and The Bahamas", AIDS Care, 26, pp.538~546 (2014)
93. Li L, "HIV-related stigma in health care settings : a survey of service providers in China", AIDS Patient Care STDS, 21, pp.753~762 (2007)
94. Turan B, "Association between perceived discrimination in healthcare settings and HIV medication adherence : Mediating psychosocial mechanisms", AIDS Behav, 21, pp.3431~3439 (2017)
95. Daughters SB, "ACT HEALTHY : a combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users", Cogn Behav Pract, 17, pp.309~321 (2010)
96. Haaga DA, "Introduction to the special section on stepped care models in psychotherapy", J Consult Clin Psychol, 68, pp.547~548 (2000)
97. Duffy M, "Integrating mental health and HIV services in Zimbabwean communities : a nurse and community-led approach to reach the most vulnerable", J Assoc Nurses AIDS Care, 28, pp.186~198 (2017)
98. Husbands W, "Case management community care for people living with HIV", AIDS(PLHAs), 2007, pp.19, 1065~1072
99. Sacks S, "Modified therapeutic community aftercare for clients triply diagnosed with HIV", AIDS and co-occurring mental and substance use disorders, 2011, pp.23, 1676~1686

관련 논문AI추천